Ai-Driven Drug Development Summit

by Biolexis | Apr 13, 2023 | News & Media

April 26-27, 2023

Biolexis CEO Dr. David J. Bearss to present MolecuLern technology at Ai-Driven Drug Development Summit Europe on April 26-27, 2023, in London.

AI Driven Drug Development Summit Europe 2023 (aidrugdevelopmentsummiteu.com)

Biolexis Therapeutics launches subsidiary Metabolexis to develop novel oral medicines for Obesity and Type 2 Diabetes to improve human longevity

October 26, 2023 Biolexis Therapeutics, a clinical-stage AI-enabled drug discovery company, today announced the launch of Metabolexis, a new pipeline company developing three targeted oral small molecules for the treatment of Obesity and Type 2 Diabetes, with the...

SOCIETY OF NEUROSCIENCE ANNUAL MEETING TO BE HELD

November 11-15, 2023 Biolexis Therapeutics Scientific Team participates and present their pre-clinical stage small molecule HDAC6 inhibitor program for ALS indication at the “SfN” (Society of Neuroscience) Annual Meeting to be held on Nov 11-15, 2023 – Walter E....

INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS

October 11-15, 2023 Biolexis Therapeutics Scientific Team participates and present their IND stage small molecule CDK9 inhibitor program for Pancreatic Cancers indications at The “AACR-NCI-EORTC” International Conference on Molecular Targets and Cancer...

« Older Entries

Ai-Driven Drug Development Summit

April 26-27, 2023

Biolexis Therapeutics launches subsidiary Metabolexis to develop novel oral medicines for Obesity and Type 2 Diabetes to improve human longevity

SOCIETY OF NEUROSCIENCE ANNUAL MEETING TO BE HELD

INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS

Admissions Consult Application: We're more interested in potential and determination than GPA

CDK9